当前位置：
X-MOL 学术
›
Digest. Dis. Sci.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases.
Digestive Diseases and Sciences ( IF 3.1 ) Pub Date : 2019-10-24 , DOI: 10.1007/s10620-019-05876-0 Andres J Yarur 1 , Alexandra Bruss 2 , Snehal Naik 3 , Poonam Beniwal-Patel 1 , Caroline Fox 1 , Anjali Jain 3 , Brandon Berens 2 , Amir Patel 1 , Ryan Ungaro 4 , Bayda Bahur 3 , Marla Dubinsky 4 , Daniel J Stein 1
Digestive Diseases and Sciences ( IF 3.1 ) Pub Date : 2019-10-24 , DOI: 10.1007/s10620-019-05876-0 Andres J Yarur 1 , Alexandra Bruss 2 , Snehal Naik 3 , Poonam Beniwal-Patel 1 , Caroline Fox 1 , Anjali Jain 3 , Brandon Berens 2 , Amir Patel 1 , Ryan Ungaro 4 , Bayda Bahur 3 , Marla Dubinsky 4 , Daniel J Stein 1
Affiliation
The original version of the article unfortunately contained a couple of errors. In 'methods' section, in 'Outcomes' subsection, the sentence 'Endoscopic remission was defined as an SESCD ≤ 2 in patients with CD and an EMS ≤ 2 in UC patients while off corticosteroids.'
中文翻译：
校正至：维多珠单抗浓度与炎症性肠病患者的长期内镜缓解有关。
不幸的是，本文的原始版本包含几个错误。在“方法”部分的“结果”小节中，句子“内镜缓解定义为CD患者中SESCD≤2，而皮质类固醇患者中EMS EMS≤2”。
更新日期：2019-11-01
中文翻译：
校正至：维多珠单抗浓度与炎症性肠病患者的长期内镜缓解有关。
不幸的是，本文的原始版本包含几个错误。在“方法”部分的“结果”小节中，句子“内镜缓解定义为CD患者中SESCD≤2，而皮质类固醇患者中EMS EMS≤2”。
京公网安备 11010802027423号